Gbowo has a membership model that allows users discounts and same-day delivery on bulk items. Photo courtesy Gbowo

A new Houston startup is combining two modern conveniences — discounted bulk prices and delivery service — into one business model.

Gbowo is a membership service where users can get same-day delivery on discounted products across several categories — food and grocery, household essentials, home & kitchen, personal care, and more.

“I started this company as a result of my frustration with the experience of bulk shopping at existing warehouse clubs, “ says Ganiu Ladejobi, CEO, in a news release. “I didn’t have a car and most of these warehouse clubs are located in parts of town that are miles away. So it would be a hassle to go there and carry all my bulk purchases back via taxi or public transportation."

The company launched with delivery coverage for Houston and has plans to expand into New York/New Jersey, Los Angeles, Chicago, and more cities this year.

“Our mission is to provide equal and convenient access to savings on quality products and services for all. For every paid membership, we will be working with local organizations to offer free membership to families located in areas where it is difficult to access quality food and products,” says Ganiu. “We are also placing a huge emphasis on supporting local emerging brands and reducing e-commerce delivery emissions so we will be using sustainable packaging and zero emissions transport as much as possible.”

Gbowo's monthly membership is priced at $19.99 monthly or $190 annually. Membership includes free same day delivery access to all products on the Gbowo website.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”